For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the projected market size of the menveo industry, and what is its expected CAGR?
The menveo market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to public immunization programs, high meningococcal disease burden, strong healthcare infrastructure, international travel requirements, and military vaccination mandates.
The menveo market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to population growth, rising healthcare awareness, increasing travel, growing school vaccine requirements, and emerging markets expansion. Major trends in the forecast period include rise in combination vaccines, focus on booster doses, increasing demand in emerging economies, enhanced cold chain distribution, and partnerships for market penetration.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20153&type=smp
What external factors are influencing the menveo market’s growth momentum?
The increasing prevalence of meningitis is expected to propel the growth of the menveo market going forward. Meningitis is an infection that causes inflammation of the protective membranes (meninges) surrounding the brain and spinal cord. It can be caused by various factors, including viral, bacterial, or fungal infections. Additionally, antibiotic resistance, weakened immune systems, and global mobility contribute to the spread of the disease. Menveo, a meningococcal vaccine, helps reduce the prevalence of meningitis by protecting against several strains of Neisseria meningitides, a leading cause of bacterial meningitis. Its widespread use in vaccination programs helps prevent outbreaks and reduce disease transmission. For instance, in August 2024, according to the UK Health Security Agency, a UK-based government agency, the meningococcal reference unit (MRU) confirmed 396 cases of invasive meningococcal disease (IMD) from 2022 to 2023, a significant increase from the 205 cases reported in 2021 to 2022. Therefore, the increasing prevalence of meningitis is driving the growth of the menveo market.
What are the major market segments driving the growth of the menveo industry?
The menveo market covered in this report is segmented –
1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine
2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination
3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults
4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/menveo-global-market-report
Which trends are expected to dominate the menveo market landscape in the coming years?
The key trend in the menveo market is developing innovative vaccine formulations, such as single-vial, fully liquid formulations, to enhance convenience, improve stability, and simplify vaccine administration. Single-vial, fully liquid formulations refer to pharmaceutical products that are pre-mixed and packaged in a single vial, with the active ingredients dissolved in a liquid form, ready for administration. For instance, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical industry company, received approval from the European Commission (EC) for a new presentation of its meningococcal vaccine, Menveo for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is now licensed for use in children aged two years and older, adolescents, and adults. The key features of the approval for the vaccine include its licensing for active immunization in the European Union for children from two years of age, adolescents, and adults, with a new single-vial, fully liquid presentation that eliminates the need for reconstitution before use.
Who are the key market players contributing to the growth of the menveo industry?
Major companies operating in the menveo market include GlaxoSmithKline (GSK) Plc
Which regions are leading the growth of the menveo market globally?
North America was the largest region in the menveo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Menveo Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20153
Need Customized Data On Menveo Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20153&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
